Skip to main content

Closed

OGN: Organon & Co. Stock Analysis | finqOS

Healthcare · Drug Manufacturers - General

Loading chart data...

Current StateBalance holding

The verdict

Good business

Strong

Revenue growth+2.2% / yr

Operating margin18.8%

ROIC2650.7%

Financially safe

Adequate

Debt / equity8.50×

Interest coverage2.4×

Current ratio1.95×

Valuation

Unrated

P/E ratio16.9×

Dividend yield0.6%

Organon & Co.

OGNNew York Stock Exchange·USD·Closed

Organon & Co.

OGNNew York Stock Exchange·USD·Closed

$13.55

+0.00%

$13.55

+$0.00 (0.00%)

52W Range

99thpctl

Volume

0.67×avg

Mkt Cap

3.56BUSD

P/E

16.9TTM

Div Yield

0.59%ann

52W Range

99thpctl

Volume

0.67×avg

Market Cap

3.56BUSD

P/E Ratio

16.9TTM

Div Yield

0.59%ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings